🔗 Share this article

Given that America proceeds with unprecedented revisions to its vaccination guidelines, a particular individual appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccinations during the global health crisis and has focused upon potential fatalities following COVID-19 vaccination in her brief tenure at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Schedule

Health officials had intended to reveal sweeping changes to the pediatric vaccine schedule recently, aligning the US with Denmark’s national calendar, according to reports – a significant shift that would place the US out of step with a large portion of the global community with no evidence for improved outcomes. The planned update has been delayed until the coming year.

Rather than Vinay Prasad, Høeg is listed to present at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this calendar year.

A Shift at the FDA

The acting appointment might represent a strengthened alliance between the drug and vaccine centers as Høeg and Prasad strengthen their influence at the FDA – and it signals a greater focus upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US in order to be more similar to the Danish model, a nation with comprehensive healthcare and a citizenry roughly the size of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, chief of the FDA’s CBER – instead of medication approval.

Concerns Over Qualifications

Dr. Høeg has little discernible background in pharmaceutical research, oversight or leadership, which has been customary for past heads of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in managing a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past heads of the center would “be deeply familiar with legal statutes and the underlying principles of drug development”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who headed the center have had.”

CDER has an immense portfolio at the agency, Woodcock emphasized.

“The public just zeroes in on the novel medication approvals, but the generic drug division authorizes thousands of generic drugs. There’s a biosimilars program, over-the-counter program and more, and each of these need to be managed,” Woodcock explained. “The thing you overlook, that is precisely what that I always told people is going to bite you.”

There is also, a significant management aspect to the job, which supervises more than 5,000 staff members. “It’s a huge administrative position, if you execute it properly,” Woodcock concluded.

Response and Contentious Initiatives

When asked about inquiries about Dr. Høeg's credentials and whether this selection indicates greater collaboration among agency officials on immunizations, a press secretary responded that the “questions are based on inaccurate premises”.

“Her experience aligns with the functions of her position,” the spokesperson stated, pointing to the time Høeg spent counseling the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's controversial priority voucher program, a controversial expedited drug-approval program that apparently concerned her preceding directors. “How are these drugs being picked for this expedited pathway? Who takes the calls?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

In general, he said, “the FDA seems to be moving towards more relaxed rules of most medications, aside from vaccines.”

Established History on Vaccines

With immunizations, Dr. Høeg has a more documented, if concerning, track record, some experts said. She published a analysis using unconfirmed crowd-sourced reports to determine the rate of heart inflammation after Covid vaccination. She counseled the Florida chief medical officer Joseph Ladapo, who was said to have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership encompassed revising rules for recently developed shots and ending “optional” vaccines, she stated after the election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of preventing teenage boys from obtaining Covid vaccinations.

“She’s an thorough ideologue who begins with her preconceived notions and tailors the evidence to retrofit the science in a very deceptive, untruthful way,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Høeg joined other contrarians, {like|